Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options

Toronto, Ontario – TheNewswire - May 22, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today announced that the board of directors has granted 1,297,000 incentive stock options to directors, officers, employees and consultants of the Company pursuant to its equity compensation plan. Each stock option is exercisable to acquire one common share of the Company at an exercise price of $1.63 per share for a period of five years from the date of grant. The options are subject to various vesting provisions in accordance with the terms of the Company's equity compensation plan and the applicable option agreements.